CC
APLS

Cipher Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Cipher Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$269K Buy
+4,568
New +$291K 0.12% 290

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cipher Capital's APLS Position: Q1 2024 in Review

Cipher Capital opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2024: 4,568 shares worth $269K. The stake represents 0.12% of the portfolio and ranks #290 among its holdings.

302 funds tracked by Wall St. Rank hold APLS as of Q1 2024.

  • Cipher Capital held 4,568 shares of Apellis Pharmaceuticals worth $269K as of Q1 2024.
  • Apellis Pharmaceuticals was a new Cipher Capital position in Q1 2024.
  • Apellis Pharmaceuticals made up 0.12% of Cipher Capital's portfolio in Q1 2024, its #290 holding.
  • 302 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2024.

Based on Cipher Capital's 13F filing for Q1 2024, filed 15 May 2024.